

© 2010. This manuscript version is made available under the  
CC-BY-NC-ND 4.0 license [http://creativecommons.org/  
licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice

Noemí Rueda<sup>1</sup>, Verónica Vidal<sup>1</sup>, María Llorens-Martín<sup>2,3,4</sup>, Susana García-Cerro<sup>1</sup>, Andrea Corrales<sup>1</sup>, Sara Lantigua<sup>1</sup>, Marcos Iglesias<sup>5</sup>, Jesús Merino<sup>6</sup>, Ramón Merino<sup>7\*</sup>, Carmen Martínez-Cué<sup>1\*</sup>

<sup>1</sup> Department of Physiology and Pharmacology, Faculty of Medicine, University of Cantabria, Santander, Spain

<sup>2</sup> Department of Molecular Neuropathology, Centro de Biología Molecular "Severo Ochoa", CBMSO, CSICUAM, Madrid, Spain.

<sup>3</sup> Network Center for Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain.

<sup>4</sup> Department of Molecular Biology, Faculty of Sciences, Universidad Autónoma de Madrid, Madrid, Spain.

<sup>5</sup> Department of Plastic and Reconstructive Surgery, Johns Hopkins School of Medicine, Baltimore, USA.

<sup>6</sup> Department of Molecular Biology, Faculty of Medicine, University of Cantabria, Santander, Spain

<sup>7</sup> Institute of Biomedicine and Biotechnology of Cantabria, Consejo Superior de Investigaciones Científicas-University of Cantabria, Santander, Spain.

\*Corresponding authors:

Carmen Martínez-Cué

Email: [martinec@unican.es](mailto:martinec@unican.es)

Telephone number: +34 942203935

Ramón Merino:

Email: [ramon.merino@unican.es](mailto:ramon.merino@unican.es)

Telephone number: +34 942206855

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Abstract:** Down syndrome (DS) is characterized by structural and functional anomalies that are present prenatally and that lead to intellectual disabilities. Later in life, the cognitive abilities of DS individuals progressively deteriorate due to the development of Alzheimer's disease (AD)-associated neuropathology (i.e.,  $\beta$ -amyloid ( $A\beta$ ) plaques, neurofibrillary tangles (NFTs), neurodegeneration, synaptic pathology, neuroinflammation and increased oxidative stress). Increasing evidence has shown that among these pathological processes, neuroinflammation plays a predominant role in AD etiopathology. In AD mouse models, increased neuroinflammation appears earlier than  $A\beta$  plaques and NFTs, and in DS and AD models, neuroinflammation exacerbates the levels of soluble and insoluble  $A\beta$  species, favoring neurodegeneration. The Ts65Dn (TS) mouse, the most commonly used murine model of DS, recapitulates many alterations present in both DS and AD individuals, including enhanced neuroinflammation. In this study, we observed an altered neuroinflammatory milieu in the hippocampus of the TS mouse model. Pro-inflammatory mediators that were elevated in the hippocampus of this model included pro-inflammatory cytokine IL17A, which has a fundamental role in mediating brain damage in neuroinflammatory processes. Here, we analyzed the ability of an anti-IL17A antibody to reduce neuroinflammation and prevent the progression of the cognitive and neuropathological alterations that are present in TS mice during early neurodevelopmental stages (i.e., hippocampal neurogenesis and hypocellularity) or that decline in later-life stages (i.e., cholinergic neuronal loss and increased cellular senescence, APP expression,  $A\beta$  peptide expression and neuroinflammation). Chronic administration of anti-IL17A partially improved the cognitive abilities of the TS mice, reduced the expression of several pro-inflammatory cytokines and normalized the APP and  $A\beta_{1-42}$  levels in the hippocampuses of the TS mice. These results suggest that IL17A-mediated neuroinflammation is involved in several AD phenotypes in TS mice and provide a new therapeutic target to reduce these pathological characteristics.

**Keywords:** Neuroinflammation, Down syndrome, Ts65Dn, anti-IL17A.

## 1. INTRODUCTION

Down syndrome (DS), the most common genetic cause of intellectual disability (Shin et al., 2009), is caused by a partial or complete triplication of human chromosome 21 (Hsa21). This intellectual disability is primarily caused by prenatal changes in central nervous system growth and differentiation (Lott, 2012; Haydar and Reeves, 2012). However, later in life, the cognitive abilities of DS individuals progressively decline due to accelerated aging and the development of Alzheimer's disease (AD)-associated neuropathology. The primary hallmarks of AD, such as the accumulation of amyloid plaques comprising  $\beta$ -amyloid ( $A\beta$ ) peptides, neurofibrillary tangles (NFTs) formed by insoluble deposits of abnormally hyperphosphorylated tau, neuroinflammation, synapse and neuronal loss, and regional atrophy, are present in 100% of individuals with DS by the fourth decade of life (Wilcock and Griffin, 2013; Lott, 2012; Cenini et al., 2012; Sabbagh et al., 2011; Lott and Dierssen, 2010; Teipel and Hampel, 2006).

This high prevalence of AD neuropathology in DS is partially related to the overexpression of several AD-related genes encoded in Hsa21. One of these genes is *APP* (Amyloid Precursor Protein), and its triplication in DS leads to an increased production of  $A\beta$  peptides. An imbalance between  $A\beta$  production and clearance leads to high levels of these peptides, causing their fast aggregation and deposition in plaques. These events induce other AD-associated neuropathologies, such as an increase in oxidative stress, neuroinflammation, and neuronal death and an accelerated decline in learning and memory (Wilcock, 2012; Sipos et al., 2007; Eikeleboom et al., 2006; Hardy, 2006; Weldon et al., 1998; Chong, 1997; Gitter et al., 1995; Hardy and Higgins 1992).

Brain inflammation is one of the most important risk factors for sporadic AD development (Guerreiro et al., 2013).  $A\beta$  peptides and APP activate glial cells (Barger and Harmon, 1997; Dickson et al., 1993), leading to cytokine and chemokine production (including Interleukin  $1\beta$

1 (IL1 $\beta$ ) and Interferon gamma (IFN $\gamma$ ) and, therefore, to increased cytokine and chemokine  
2 expression in the AD brain (Meager 2004; 2005; Ho et al., 2005). Cytokines can also induce A $\beta$   
3 generation, tau phosphorylation and oxidative stress (Steel et al., 2007; Blurton-Jones and  
4 Laferla, 2006; Sastre et al., 2003). The combination of the activities of some of these cytokines  
5 (e.g., IL1 $\beta$  and IFN $\gamma$ ) substantially elevates A $\beta$  secretion and its cellular accumulation (Blasko et  
6 al., 2001). Therefore, inflammation can directly influence plaques and NFT formation, and these  
7 two neuropathological events can, in turn, increase inflammation.  
8  
9

10  
11  
12  
13  
14  
15  
16  
17 The neuroinflammatory changes present in the DS brain include microglial and astroglial  
18 activation and increased levels of pro-inflammatory cytokines (Wilcock and Griffin, 2013; Griffin,  
19 2006; Park et al., 2005; Griffin et al., 1989). This neuroinflammatory response exacerbates  
20 oxidative stress, synaptic dysfunction and neuronal death, and decreases neurogenesis (Lyman  
21 et al., 2014; Town et al., 2005; Llorens-Martin et al., 2014; Fuster-Matanzo et al., 2013).

22  
23  
24  
25 Specifically, cytokines affect proliferation, new neuron maturation and neuronal recruitment into  
26 relevant circuits (Rosi et al., 2012). Because neurogenesis is impaired in DS individuals (see  
27 Rueda et al., 2012), neuroinflammation increases their vulnerability to lesions that might  
28 contribute to the early onset of dementia (Teipel and Hampel, 2006). Thus, reducing  
29 neuroinflammation may be a therapeutic strategy for preventing AD pathology in DS and may  
30 contribute toward stimulating endogenous repair mechanisms, such as the formation of new  
31 neurons.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47  
48 The most commonly used model of DS is the partial trisomic mouse Ts65Dn (TS) (Sturgeon and  
49 Gardiner, 2011). TS mice replicate many DS phenotypes, including alterations in behavior,  
50 learning and memory, brain morphology and hypocellularity, neurogenesis, neuronal connectivity  
51 and electrophysiological and neurochemical processes (Rueda et al., 2012; Bartesaghi et al.,  
52 2011). As in DS and AD individuals, the TS mouse shows age-dependent degeneration, including  
53 the loss of cholinergic and noradrenergic neurons and increased levels of APP, A $\beta$  peptides and  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 oxidative stress, starting at the age of 6 months (Corrales et al., 2014; 2013; Lockrow et al., 2009;  
2 Shichiri et al., 2011). However, these animals do not show amyloid plaques or NFTs (see Rueda  
3 et al., 2012; Rueda et al., 2010; Netzer et al., 2010; Seo et al., 2005; Millan Sanchez et al., 2012).  
4  
5 TS mice also exhibit increased neuroinflammation due to microglial activation in the hippocampus  
6  
7 and medial septum and due to the altered expression of inflammatory cytokines in the brain  
8  
9 (Lockrow et al., 2011; Hunter et al., 2004; Robertson et al., 2012). As in DS, the inflammatory  
10  
11 events in TS mice can precede, or be simultaneous to, other degenerative processes. Microglial  
12  
13 activation may play a significant role in cholinergic degeneration and other pathological hallmarks  
14  
15 of AD, and reducing neuroinflammation may provide protection against neurodegeneration. In  
16  
17 fact, the administration of minocycline, a synthetic tetracycline with anti-inflammatory properties,  
18  
19 ameliorates the cognitive deficits and neurodegenerative phenotypes of TS mice (Hunter et al.,  
20  
21 2004).  
22  
23  
24  
25  
26  
27  
28

29 In the present study, we have observed increased levels of several pro-inflammatory mediators in  
30  
31 the hippocampi of 12-month-old TS mice, and we have highlighted the increased levels of IL17A,  
32  
33 due to its role in mediating brain damage through its potent pro-inflammatory actions (Meares et  
34  
35 al., 2012; Zimmerman et al., 2013). IL17A is a homodimeric glycoprotein produced by Th17  
36  
37 helper T cells; furthermore, IL17A participates in the development of autoimmunity, inflammation  
38  
39 and tumoral immunity and plays a role in the host defense against bacterial and fungal infections  
40  
41 (Wu et al., 2015; Murugaiyan et al., 2015; Flores-García and Talamás-Rohana, 2012). The  
42  
43 increased production of IL17 is associated with several inflammatory disorders (Beringer et al.,  
44  
45 2016). However, the role of IL17A in AD pathophysiology is unclear. In a rat model of AD, the  
46  
47 increased expression of IL17 in the hippocampus after Th17 cell infiltration into the brain  
48  
49 parenchyma aggravates neuroinflammation and neurodegeneration (Zhang et al., 2013). In  
50  
51 addition, in the APP/PS1 mouse model of AD, the infiltration of IL17-producing T cells after  
52  
53 infection with a common human pathogen increases glial activation and amyloid- $\beta$  deposition  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

(McManus et al., 2014). Conversely, Yang et al. (2017) have demonstrated that intracranial IL17A overexpression decreases cerebral amyloid angiopathy in another mouse model of AD. The mechanism of action of IL17A in astrocytes, microglia and neurons involves the binding of IL17A to its receptor, which activates inflammatory pathways, thereby inducing the expression of pro-inflammatory genes through a signaling pathway that ends with the activation of the transcriptional factor NF- $\kappa$ B. NF- $\kappa$ B is implicated in astrocytosis and microglial activation, inducing the expression of other pro-inflammatory cytokines, such as IL6, TNF $\alpha$ , and IL1 $\beta$ , and several chemokines (Korn et al., 2009).

Because of its fundamental role in mediating the brain damage of neuroinflammatory processes (Meares et al., 2012; Zimmerman et al., 2013; Korn et al., 2009), blocking this cytokine has become a promising strategy for anti-inflammatory therapies. IL17A inhibitors have shown beneficial effects in different autoimmune pathologies, such as experimental autoimmune encephalitis (Uyttenhove and Van Snick, 2006; Mardiguian et al., 2013) and multiple sclerosis (Deif et al., 2013). In addition, the administration of anti-IL17A antibodies reduces inflammation and improves the neurological outcomes of different CNS pathologies, such as the recovery after stroke, ischemia or encephalic inflammation, in which an important inflammatory component exists (Dallenbach et al., 2015; Swardfager et al., 2013; Flores-García and Talamás-Rohana, 2012; Gelderbrom et al., 2012). Accordingly, here, we have evaluated the effects of anti-IL17 treatment with an anti-IL17A monoclonal antibody (mAb) on reducing neuroinflammation and on improving cognition, neuromorphological alterations and AD-like neurodegenerative features in the TS mouse model of DS.

## 2. MATERIALS AND METHODS

### 2.1. *Animals and pharmacological treatments*

1 Mice were generated by repeated backcrossing of TS females with C57C3HF1 males. To  
2 determine the presence of the trisomy, animals were karyotyped using real-time quantitative PCR  
3 (qPCR) as previously described (Liu et al., 2003). C3H/HeSnJ mice carry a recessive mutation  
4 that leads to retinal degeneration (Rd). Therefore, all animals were genotyped using standard  
5 PCR to detect the *Rd* mutation (Bowes et al., 1993). Experiments were conducted using wt/wt or  
6  
7 Rd1/wt animals. Mice were housed under standard laboratory conditions with an inverted  
8  
9 dark/light cycle (lights off at 8:00 A.M. and on at 8:00 P.M.). In all experiments, TS mice were  
10 compared to euploid littermates (CO).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 A total of 72 male mice, aged 7 months at the beginning of treatment, were used and assigned to  
23 one of six experimental groups: CO saline (n=10), TS saline (n=10), CO anti-IL17 (n=13), TS anti-  
24 IL17 (n=13), CO IgG1-C (n=13) and TS IgG1-C (n=13).  
25  
26  
27  
28  
29  
30

31 The hybridoma cell line MM17F3, which produced a murine IgG1 anti-mouse IL17A mAb, was a  
32 kind gift from Dr. Jacques Van Snick (Ludwig Institute for Cancer Research, Brussels, Belgium).  
33  
34 Because polyclonal IgGs may have immunomodulatory activities that are independent of their  
35 antigen specificities and because polyclonal IgGs have been used to treat different immunological  
36 disorders, such as immunodeficiencies and various inflammatory autoimmune diseases  
37 (Zuercher et al., 2016), one group of TS mice and another group of CO mice were treated with a  
38 mouse IgG1 anti-TNP isotype control mAb (IgG1-C) and used as vehicle control groups.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 From 7 to 11 months of age, the mice in the six groups were injected intraperitoneally with saline  
51 or with 0.5 mg/week (in two injections per week) anti-IL17A or IgG1-C.  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 The behavioral experiments were initiated at 11 months of age and performed for 4 weeks.

2 During this period, the animals received anti-IL17A, IgG1-C or saline until the end of the  
3 behavioral characterization, when they were sacrificed.  
4  
5  
6  
7  
8

9 In view of the lack of differences between the IgG1-C- and saline-treated groups in the behavioral  
10 assessment and cytokine analyses, the neuromorphological, APP and A $\beta$  determinations were  
11 carried out only in CO and TS mice treated with the mAb (vehicle) or anti-IL17A.  
12  
13  
14  
15  
16  
17  
18

## 19 **2.2. Sacrifice**

20 After completing the behavioral tests, all animals were perfused with saline. To perform  
21 histological analyses the left hemispheres of 7 animals from the CO IgG1-C, TS IgG1-C, CO anti-  
22 IL17 and TS anti-IL17 groups were fixed overnight in 4% paraformaldehyde, transferred into 30%  
23 sucrose and frozen on dry ice.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 To perform the Western blot, ELISA and array experiments, the right hemispheres of the 7  
37 animals used for histological analyses and the whole brains of the animals that were used in the  
38 behavioral battery (but not in the histological experiments) were immediately dissected and  
39 frozen.  
40  
41  
42  
43  
44  
45  
46

## 47 **2.3. Cytokine antibody array**

48 One-half of the right hippocampus of each of 10 animals from each of the six experimental groups  
49 was used to perform a cytokine protein array. Each array was performed on two independent  
50 groups of 5 mice from each experimental condition. Samples were homogenized, and protein  
51 concentrations were estimated using the BCA Protein Assay Kit (Pierce, Rockford, IL, USA). For  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 each independent group, a pooled protein extract for each experimental condition was prepared  
2 in a single tube. The total protein concentration was determined for each mouse to ensure an  
3 equal amount of protein corresponding to each animal in the prepared mixture. The mouse  
4 cytokine array (RayBio® C-series Mouse Cytokine Antibody Array C1000; Ray Biotech Inc.,  
5 Norcross, GA, USA) consisted of 96 soluble signaling factors and cytokine antibodies spotted in  
6 duplicate onto a PVDF membrane. The membranes were blocked with 10% bovine serum  
7 albumin (BSA) in phosphate-buffered saline (PBS) and subsequently incubated with samples  
8 overnight at 4 °C. The membranes were washed with buffer supplied by the manufacturer and  
9 exposed to 500-fold diluted biotin-conjugated anti-cytokine antibodies at room temperature (RT)  
10 for 2 h. The membranes were then washed, incubated with 1000-fold diluted HRP-conjugated  
11 streptavidin for 1 h, and immersed for 1 min in a peroxidase substrate solution. For each spot, the  
12 net density of the gray level was normalized by subtracting the background from the total raw  
13 density using the Chemidoc XRS system and ImageJ analysis software. For each group of  
14 animals, the relative levels of each cytokine were calculated.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

## 36 **2.4. Behavioral analysis**

### 37 2.4.1. Learning and memory

38  
39  
40  
41 To evaluate spatial learning and memory, the platform-relocation protocol of the Morris water  
42 maze was used (Saab et al., 2011; Chen et al. 2000; Steele and Morris 1999). This protocol was  
43 chosen because the Morris water maze is a more difficult task that provides better discrimination  
44 between cognitive performances in different experimental manipulations.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 The apparatus consisted of a circular 110-cm-diameter tank filled with water (22-24 °C) that was  
2 made opaque by the addition of powdered milk. Inside the tank, a platform was hidden 1 cm  
3  
4 below the water level. Animals were tested in 12 consecutive daily sessions as follows: eight  
5  
6 acquisition sessions (platform submerged), followed by four cued sessions (platform visible). All  
7  
8 trials were videotaped with a camera located 2 m above the water level. The Anymaze  
9  
10 computerized tracking system (Stoelting, Wood Dale, IL, USA) was used to analyze the mouse  
11  
12 trajectories and measure the escape latency for each animal in the trial.  
13  
14  
15

16  
17 In the acquisition sessions (S1-S8), the platform was hidden 1 cm below the water level. From  
18  
19 one daily session to the next, the platform was placed in a different location (E, SW, center, and  
20  
21 NW); each position was used once every four consecutive daily sessions. Each of the eight  
22  
23 acquisitions and four cued sessions (one per day) consisted of four pairs of trials that were 30-45  
24  
25 min apart. For each pair of trials, the mice were randomly started from one of four positions (N, S,  
26  
27 E, W), which was held constant for both trials. The first trial of a pair was terminated when the  
28  
29 mouse located the platform or when 60 s had elapsed. The second trial commenced following a  
30  
31 period of 20 s, during which the animal was allowed to stay on the platform. Several fixed cues  
32  
33 outside of the maze were constantly visible from the pool.  
34  
35  
36  
37  
38  
39

40 During the cued sessions, the platform was visible, the water level was 1 cm below the platform,  
41  
42 and its position was indicated with a flag. Eight trials were performed during each session using  
43  
44 the same experimental procedure as in the acquisition sessions. The mean latency of all trials in  
45  
46 all cued sessions is presented.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 2.4.2. Side effects

### 2.4.2.1 Motor abilities

#### *Spontaneous activity:*

The Acti-system II device (Panlab, Barcelona) was used to measure daily variations in the spontaneous locomotor activity of the animals during a complete 12/12 h light/dark cycle.

#### *Sensorimotor function and motor coordination:*

Sensorimotor function was evaluated with a battery of tests, and motor coordination was evaluated with the rotarod test, following the procedures described by Martínez-Cué et al. (2013).

In the visual placing reflex test, cerebellar and vestibular functions were evaluated. In 3 consecutive trials, mice were gently lowered by the tail toward a flat surface from a height of 15 cm. The forepaw-extension response was scored on a 0-4 scale [4: forepaws extended when placed at the highest level; 3: forepaws extended before the vibrissae touched the surface; 2: forepaws extended after the vibrissae touched the surface; 1: forepaws extended after the nose touched the surface; or 0: no extension].

To evaluate auditory sensitivity, the startle response to a sudden auditory stimulus was measured. Mice were placed facing the wall of an unfamiliar cage, and the auditory stimulus was generated by clapping two stainless steel forceps (7 cm long) together. A score (0-3 points) was assigned based on the magnitude of the response: jumping more than 1 cm (3 points); jumping less than 1 cm (2 points); retracting the ears (Preyer reflex, 1 point); or no response (0 points).

1 The vibrissa-placing reflex was analyzed by noting the reflexive reaction to touching the vibrissae  
2 with a cotton stick. In three consecutive trials, a score of 1 was assigned to animals that touched  
3 the stimulated vibrissae with an ipsilateral paw, and a score of 0 was assigned if no response was  
4 evident.  
5  
6  
7  
8  
9

10  
11 Grip strength was assessed by quantifying the resistance to being separated from a lid of  
12 aluminum bars (2 mm), when dragged by the tail (0: no resistance, total loss of grip strength; 1:  
13 slight resistance; 2: moderate resistance; 3: active resistance; or 4: extremely active resistance,  
14 normal grip strength).  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 To evaluate the equilibrium, four 20-s trials of balance were performed on an elevated (40-cm-  
25 high), horizontal (50-cm-long) rod. Trials 1 and 2 were performed on a flat wooden rod (9 mm  
26 wide), and trials 3 and 4 were performed on a cylindrical aluminum rod (1 cm in diameter). In  
27 each trial, the animals were placed in a marked central zone (10 cm) on the elevated rod. A score  
28 of 0 was assigned if the animal fell within 20 s, 1 if the animal stayed within the central zone for  
29 >20 s, 2 if the animal left the central zone, and 3 if the animal reached one of the ends of the bar.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 The prehensile reflex (three 5-s trials) was measured as the ability of the animal to remain  
42 suspended by the forepaws by grasping an elevated horizontal wire (2 mm in diameter). The  
43 maximum possible score of 3 was achieved when the animal remained suspended by the  
44 forepaws in all three trials (one point per trial). Traction capacity was scored at simultaneously by  
45 assessing the number of hind limbs that the animal raised to reach the wire (0: none; 1: one limb;  
46 or 2: two limbs).  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

#### *Motor coordination: rotarod*

Motor coordination was evaluated using a rotarod device (Ugo Basile; Comerio, Italy), which consisted of a 37-cm-long, 3-cm-in-diameter plastic rod that rotated at different speeds. In a single session, 4 trials with a maximum duration of 60 s each were performed. In the first three tests, the rod was rotated at constant speeds of 5, 20 and 40 r.p.m., respectively. The last trial consisted of an acceleration cycle, in which the rod rotated progressively faster, and the animal had to adapt to the growing demands of the test. The length of time that each animal stayed on the rotarod during the acceleration cycle was recorded.

#### 2.4.2.2. Anxiety

Anxiety and general activity in the open field and plus maze tests were evaluated according to the procedures described by Martínez-Cué et al. (2013).

#### *Open field:*

Exploratory behavior and anxiety were assessed using a square-shaped open field (55 cm x 55 cm, surrounded by a 25-cm-tall fence), divided into 25 equal squares. The mice were placed in the center of the field, and the number of vertical (rearing) activities and horizontal crossings (from square to square, subdivided into center vs. peripheral crossings) was scored in a single 5-min trial.

#### *Plus maze:*

The elevated plus maze consisted of two closed arms (5 cm x 30 cm, with clear perplex walls that were 15 cm high) and two open arms (5 cm wide x 30 cm long) that were raised 40 cm from the floor. In a single 5-min trial, the mice were placed in the center of the maze. The trials were

1 videotaped, and the number of arm entries, the time spent in the open and closed arms and the  
2 initial freezing time were measured with the Anymaze computerized tracking system.  
3  
4  
5

## 6 7 **2.5. Histological and stereological procedures**

### 8 9 10 11 2.5.1. Tissue preparation

12  
13  
14  
15  
16  
17 The brains were coronally sliced using a cryostat. Fifty- and thirty- $\mu$ m-thick sections of the  
18 hippocampal and medial septum areas, respectively, were collected into culture plates as  
19 previously described (Corrales et al., 2014).  
20  
21  
22

### 23 24 25 26 2.5.2. Nissl staining

27  
28  
29  
30  
31 To calculate the total area of the subgranular zone (SGZ) of each mouse, a randomly chosen  
32 series was used to perform Nissl staining. The area of the SGZ was measured with the standard  
33 Cavalieri method using a semiautomatic system (ImageJ v.1.33, NIH, USA,  
34 <http://rsb.info.nih.gov/ij/>),  
35  
36  
37  
38  
39  
40  
41  
42

### 43 44 2.5.3. Cell proliferation in the SGZ (Ki67 immunofluorescence)

45  
46  
47  
48 Slices were initially pre-incubated in phosphate buffer (PB) with 0.5% Triton X-100 and 0.1%  
49 BSA, and then, immunohistochemistry was performed. Briefly, free-floating slices were incubated  
50  
51 with primary antibodies (rabbit anti-Ki67 (1:750; Abcam, Cambridge, UK)) diluted in PB with 0.5%  
52  
53 Triton X-100 and 0.1% BSA (PBTBSA) for two days at 4°C. Then, slices were incubated  
54  
55  
56  
57  
58 overnight at 4 °C with the secondary antibody (donkey anti-rabbit-Alexa Fluor 488 (1:1,000,  
59  
60  
61  
62  
63  
64  
65

1 Molecular Probes, Eugene, OR, USA). The sections were counterstained with 4'6-diamidino-2-  
2 phenylindole (DAPI) and mounted onto gelatin-covered slides to be analyzed and photographed.  
3  
4 The total number of Ki67-positive cells in the selected sections was counted with the help of an  
5 optical fluorescence microscope (Zeiss Axioskop 2 plus, 40x objective) using the previously  
6 described optical dissector method (Corrales et al., 2014).  
7  
8  
9  
10  
11  
12  
13

#### 14 2.5.4. Mature granule cell count

15  
16  
17  
18

19 Mature granule cells in the hippocampal granule cell layer (GCL) were counted in a series of one-  
20 in-nine sections stained with DAPI (Calbiochem, Billerica, MA, USA; 1:1,000) for 10 min in 0.1 M  
21 PB. Cell counts were performed using a previously described physical dissector system coupled  
22 with confocal microscopy (Llorens-Martin et al., 2006). Random numbers were generated to  
23 select the points at which to locate the dissectors. Six dissectors in each section were measured.  
24 At the selected points, the confocal microscope (Leica SPE, Leica Microsystems, Wetzlar,  
25 Germany) was directed toward a position previously established randomly inside the GCL. Next,  
26 at each point, a series of confocal images was serially recorded, keeping to the general rules of  
27 the physical dissector and the unbiased stereology. The confocal images were then analyzed on  
28 a computer with the aid of ImageJ software (ImageJ, v. 1.33, NIH, Bethesda, MD, USA,  
29 <http://rsb.info.nih.gov/ij>). Every successive pair of images was used, with one considered as the  
30 reference image and the other as the sample image. Next, the sample image became the  
31 reference image for the following pair of images, and so on. The cells were counted with the NIH  
32 ImageJ Cell Counter, labeling each cell on the screen the first appearance of the cell in the series  
33 of confocal images. The software generated the total number of cells when the dissector brick  
34 was completed. To count the mature granule neurons in the GCL, the dissector frame was  
35 configured into the shape of a square situated randomly inside the GCL. The number of cells was  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 then divided by the reference volume of the dissector (this parameter was the volume of a cube  
2 formed by the area of the frame multiplied by the height of the dissector) to obtain the number of  
3  
4 cells per unit of volume (cell density).  
5  
6  
7  
8

#### 9 2.5.5. Immunocytochemical detection of ChAT

10  
11  
12  
13  
14 The series of brain slices containing the medial septum randomly comprised 1 section out of  
15 every 6 slices. After inactivation of endogenous peroxidase for 30 min in 3% hydrogen peroxide,  
16  
17 the slices were washed three times in PBS and blocked for 1 h in PBS containing 20% normal  
18  
19 donkey serum (NDS) and 0.2% Triton X-100 prior to overnight incubation at RT with a mixture  
20  
21 containing the primary antibody (goat polyclonal Anti-ChAT, Chemicon/Millipore; Billerica, MA,  
22  
23 USA; 1:100). After 3 10-min rinses in PBS, the sections were incubated for 2 h in biotinylated  
24  
25 secondary antibody (anti-goat, Vector Laboratories; Peterborough, UK; 1:250) diluted in 2% NDS/  
26  
27 PBS at RT. The sections were rinsed three times in PBS and incubated for 1 h at RT in a  
28  
29 streptavidin-biotin complex (Vectastain ABC Kit, Vector Laboratories) in PBS for 1 h at RT.  
30  
31  
32  
33  
34 Following a thorough rinse with PBS, immunohistochemical staining was visualized by incubation  
35  
36 with 3,3'-diaminobenzidine solution (Vector Laboratories). After immunostaining, the sections  
37  
38 were mounted on Superfrost plus glass slides, dehydrated, cleared, and coverslipped with  
39  
40 mounting medium. All ChAT-positive cells in the medial septum area were counted using a Zeiss  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

#### 51 **2.6. Senescence: histochemical detection of senescence-associated $\beta$ -galactosidase**

52  
53  
54  
55  
56 To estimate the density of senescent cells in the SGZ of the dentate gyrus (DG) in the different  
57  
58 groups of mice, we used the SA- $\beta$ -gal (senescence-associated  $\beta$ -galactosidase) method  
59  
60  
61  
62  
63  
64  
65



1 described by He et al. (2013). The hippocampal sections were washed twice with PBS and fixed  
2 for 15 min at RT with a 0.5% glutaraldehyde solution. Next, the sections were washed and  
3  
4 incubated with a staining solution containing 5-bromo-4chloro-3-indolyl- $\beta$ -D-galactopyranoside (X-  
5 gal, Thermo Fisher Scientific, MA, USA) for 24 h at 37 °C, mounted on Superfrost plus glass  
6  
7 slides, dehydrated, cleared, and coverslipped with mounting medium. The density of SA- $\beta$ -gal-  
8  
9 positive cells (showing a blue reaction product over the cell soma) was determined by counting all  
10  
11 blue cells in the SGZ of the DG of each animal using a Zeiss Axioskop 2 plus microscope with a  
12  
13 40X objective and dividing this number by the area of the SGZ.  
14  
15  
16  
17  
18  
19  
20  
21

## 22 **2.7. APP protein and A $\beta$ -peptides levels**

23  
24  
25  
26 The levels of APP protein and A $\beta$ -peptides were measured in cortical and hippocampal tissues of  
27  
28 TS and CO animals treated with IgG1-C or anti-IL17 (six animals per group) by Western blot and  
29  
30 ELISA respectively as previously described by Corrales et al, (2013).  
31  
32  
33  
34  
35

### 36 2.7.1. APP levels: Western blotting

37  
38  
39  
40  
41 The cortices and hippocampi from 11-12-month-old animals were dissected and stored at -80 °C  
42  
43 for the immunodetection of APP. Whole-cell lysates from the cortex or hippocampus were  
44  
45 prepared as previously described (Rueda et al., 2010). The total protein content of each sample  
46  
47 was determined using the method described by Lowry et al. (1951). Identical amounts of total  
48  
49 protein (10  $\mu$ g) from each sample were loaded on a 10% sodium dodecyl sulfate-polyacrylamide  
50  
51 gel, electrophoresed, and transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad,  
52  
53 Hercules, CA, USA) using a Mini Trans-Blot Electrophoresis Transfer Cell (Bio-Rad). The efficient  
54  
55 transfer of proteins was confirmed by staining the PVDF membrane with Ponceau red (Sigma-  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Aldrich, St. Louis, MO, USA). Non-specific binding of antibodies was prevented by incubating the  
2 membranes in TBST buffer (10 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.05% Tween 20) containing  
3  
4 5% non-fat milk powder. The blots were incubated with the monoclonal mouse primary antibody  
5  
6 (raised against an N-terminal epitope of APP; 1:2000, Chemicon/Millipore; Billerica, MA, USA)  
7  
8 diluted in TBST containing 2% non-fat milk powder overnight at 4 °C. After extensive washing  
9  
10 with TBST, the blots were incubated with the appropriate peroxidase-labeled secondary antibody  
11  
12 (1:40.000, Jackson Labs, West Grove, PA, USA) for 1 h at RT in the TBST-dry milk buffer.  
13  
14  
15  
16  
17  
18

19 After the membranes were washed, immunoreactivity was detected with an enhanced  
20  
21 chemiluminescence Western blot detection system (ECL Advanced; Amersham-Biosciences,  
22  
23 Arlington Heights, IL, USA) and visualized with an Image Quant 350 (GE Healthcare). The  
24  
25 integrated optical densities of the bands were then estimated using Scion Image (Scion,  
26  
27 Frederick, MD, USA) and normalized to background values. Relative variations between the  
28  
29 bands of the TS and CO mice were calculated on the same film. Duplicates of each sample were  
30  
31 run on each gel. At least four independent gels were run for each sample. Measurements were  
32  
33 within the linear range. To ensure equal protein loading across samples, the blots were reprobbed  
34  
35 with a mouse monoclonal anti-GAPDH antibody.  
36  
37  
38  
39  
40  
41  
42

### 43 2.7.2. Quantification of A $\beta$ <sub>1-40</sub> and A $\beta$ <sub>1-42</sub> in brain tissue

44  
45  
46  
47  
48 Sandwich A $\beta$  ELISA was used to measure the hippocampal and cortex levels of A $\beta$ <sub>1-40</sub> and A $\beta$ <sub>1-42</sub>  
49  
50 in 6 animals from each group. Briefly, the tissue samples were weighed and homogenized in 8X  
51  
52 cold 5 M guanidine hydrochloride buffer (pH 8.0) and incubated for 3 h at RT. Samples were  
53  
54 diluted with standard dilution buffer (1:10) and centrifuged at 16,000 g for 20 min at 4 °C to  
55  
56 remove insoluble material. The supernatant fraction was collected and stored at -80 °C. To  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 quantify the A $\beta$  levels, the supernatant fractions were analyzed with well-established mouse A $\beta$ -  
2 40 and A $\beta$ <sub>1-42</sub> ELISA kits (KMB 3481 and KMB 3441, respectively; Invitrogen, Carlsbad, CA, USA),  
3 following the manufacturer's instructions. Analyses were always performed in duplicate. OD450  
4 values were measured on a microplate reader (Multiskan EX, Thermo Electron Corporation). The  
5 A $\beta$ <sub>1-40</sub> and A $\beta$ <sub>1-42</sub> levels were calculated according to a standard curve.  
6  
7  
8  
9  
10  
11  
12  
13

## 14 **2.8. Statistical analysis**

15  
16  
17  
18

19 The water maze data of the acquisition sessions (sessions 1-8) were analyzed using two-way  
20 ANOVA with repeated measures (RM) ('session' x 'genotype' x 'treatment' or 'trial' x 'genotype' x  
21 'treatment'). The rest of the data were analyzed using two-way ('genotype' x 'treatment') ANOVA.  
22  
23 The mean values of each experimental group were compared post hoc with Student's t-tests if  
24 two groups were compared or with Bonferroni tests if more than two groups were compared. All  
25 analyses were performed using SPSS for Windows version 22.0.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

### 3. RESULTS

#### 3.1. Inflammatory microenvironment in the hippocampus of TS mice: effect of anti-IL17 treatment.

Because increased neuroinflammation is implicated in AD neuropathology and in the characteristic neurodegeneration of DS and TS mice (Wilcock and Griffin, 2013; Hunter et al., 2004; Robertson et al., 2012; Mulet et al., 2017), we first explored the expression pattern of a large panel of soluble immune mediators in the hippocampi of TS mice and CO mice.

Of a panel of 96 immune mediators, only eight were significantly modified in the TS animals.

**Figure 1** shows the expression levels of the cytokines and chemokines that were altered in these mice, while **Table 1** presents the results of the multivariate analysis of each immune mediator selected.

The levels of the pro-inflammatory mediators IL17A, IFN- $\gamma$ , IL1 $\beta$ , IL15, IL3, MIP3 $\alpha$  (Macrophage Inflammatory Protein-3), and Granulocyte-colony stimulating factor (G-CSF) were significantly higher in the hippocampi of the TS mice than in the hippocampi of the CO animals. In addition, the expression of the chemokine CXCL12 was reduced in the hippocampi of the TS compared to the hippocampi of the CO mice.

The hippocampal expression of these pro-inflammatory mediators was not modified by the chronic treatment of the TS or CO mice with IgG1-C compared to the saline-treated TS or CO mice (**Table 1**).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

To explore whether the increased expression of IL17A observed in the hippocampi of the TS mice was involved in the inflammatory milieu observed in the hippocampi of these animals, we determined whether chronic inhibition of this cytokine with the anti-IL17A mAb normalized the levels of the cytokines and chemokines that were altered. The administration of anti-IL17A mAb, but not of IgG1-C, caused a notable reduction in the hippocampal expression levels of the pro-inflammatory mediators IL17A, IFN $\gamma$ , IL1 $\beta$ , IL15, MIP3 $\alpha$  and G-CSF in the TS mice (**figure 1, Table 1**). In fact, the anti-IL17A treatment normalized the levels of these inflammatory mediators in the TS mice, evidenced by levels that were equivalent to those of the IgG1-C- or saline-treated CO mice. However, *post hoc* comparison showed that anti-IL17 did not modify the levels of these inflammatory mediators in the hippocampi of the CO mice (IL17A: p=0.65; IFN- $\gamma$ : p=0.31; IL1 $\beta$ : p=0.55; IL15: p=0.28; IL3: p=0.90; MIP3 $\alpha$ : p=0.085; G-CSF: p=0.33; and CXCL12: p=0.07).

### 3.2. Anti-IL17 administration improved the cognitive performances of the TS and CO mice in the Morris water maze without affecting their motor or motivational abilities

The difficulties in escaping from the water maze were greater for the TS animals under all treatments than for the CO mice (p<0.001; **figure 2A**). Anti-IL17 administration improved the learning abilities of both the TS and CO animals, as demonstrated by their reduced latencies in escaping from the water maze compared with those of the IgG1-C-treated animals of the same genotype (p=0.008; **figure 2C**). In addition, the performances of the TS and CO mice that received IgG1-C did not differ from those that received saline (**figure 2B**). Therefore, the treatment with the isotype control IgG1-C did not alter cognition in the animals.

When the learning curves of each pair of groups (differing in phenotype or treatment) were analyzed *post hoc*, a large difference was found between the performance of the IgG1-C-treated

1 TS and that of the CO mice ( $p < 0.001$ ). However, the anti-IL17 treatment reduced these  
2 differences since the difference between the learning curves of the IgG1-C-treated CO animals  
3 and anti-IL17-treated TS animals was no longer significant (**figure 2C**).  
4  
5  
6

7  
8  
9 Next, the strategy used by the animals to search for the platform, namely, procedural learning,  
10 was analyzed. The TS animals spent more time swimming in the periphery of the maze than the  
11 CO animals ( $p < 0.001$ ; **figure 2D**). However, the time spent by the IgG1-C-treated TS and CO  
12 mice in the periphery did not differ from the time spent by the saline-treated mice of the same  
13 genotype (**figure 1E**), and the anti-IL17 treatment slightly reduced the thigmotactic behavior of  
14 the mice, although this effect was not statistically significant ( $p = 0.057$ ; **figure 2F**).  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 During the cued trials the six groups of animals did not differ significantly in their latency to reach  
27 the platform when it was visible (**figure 2G**). In addition, no significant differences were found in  
28 the swimming speeds of the six groups of animals during the acquisition or cued trials (data not  
29 shown). Therefore, the differences in performance found between the groups of mice during the  
30 acquisition sessions were unlikely to be due to changes in their motor or motivational abilities.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 **3.3. Anti-IL17 treatment ameliorated the deficits in cell proliferation and survival in the TS** 42 **mice, without affecting their CO littermates** 43 44 45

46 The vehicle-treated TS group (TS IgG1-C) showed impaired proliferation in the SGZ of the DG,  
47 as demonstrated by a reduced density of Ki67+ cells in the area ( $p = 0.012$ ; **figure 3B**). Chronic  
48 administration of anti-IL17 increased the density of proliferating cells in the TS group ( $p = 0.049$ ),  
49 but no effect was evident in the CO group. Although the anti-IL17 treatment did not completely  
50 rescue the defective proliferation found in the vehicle-treated TS group, the density of proliferating  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

cells in the SGZ did not significantly differ between the anti-IL17-treated TS group and the CO vehicle group (p=0.084).

When the number of DAPI+ cells was analyzed, the TS group showed a marked hypocellularity (p<0.001). After chronic treatment with anti-IL17, the TS group showed less marked hypocellularity, as demonstrated by the slight increase in the density of DAPI+ cells (**figure 4**), although this effect was not statistically significant.

### **3.4. The cholinergic neurodegeneration and enhanced cellular senescence found in TS animals was ameliorated after anti-IL17 administration**

The vehicle-treated TS group (TS IgG1-C) showed a decreased density of cholinergic neurons in the basal forebrain compared to the CO group (p=0.027; **figure 4**). However, after treatment with anti-IL17, the density of ChAT+ cells become higher in the TS group than in the vehicle-treated group of the same genotype, but this effect was not statistically significant.

The IgG1-C-treated TS group also displayed a larger population of cells with a senescent phenotype in the hippocampus than the CO group (p<0.01; **figure 5**). After the anti-IL17 treatment, the TS group showed a reduction in the density of senescent cells compared to the vehicle-treated group; however, this effect was not statistically significant.

Anti-IL17 administration did not modify the density of ChAT+ or senescent cells in the CO mice.

### **3.5. Anti-IL17 administration normalized the protein expression levels of APP and the A $\beta$ <sub>1-42</sub> peptide in the hippocampi, but not in the cortices, of TS mice**

1  
2 The TS group showed enhanced protein levels of APP in the cortex ( $p < 0.001$ ) and hippocampus  
3  
4 ( $p = 0.001$ ; **figure 7A**). These levels were reduced by the anti-IL17 treatment in the hippocampi of  
5  
6 the TS animals ( $p = 0.003$ ) but not in the cortices.  
7  
8  
9

10  
11 In addition, the TS animals showed enhanced expression of  $A\beta_{1-42}$  in the hippocampi ( $p = 0.023$ ;  
12  
13 **figure 7B**) that was completely rescued after the administration of anti-IL17. This treatment also  
14  
15 reduced the levels of  $A\beta_{1-42}$  in the CO animals ( $p = 0.001$ ). However, the amount of  $A\beta_{1-42}$  found in  
16  
17 the cortices did not differ significantly between the four groups of mice (**figure 7B**).  
18  
19  
20  
21  
22

23  
24 The TS mice also showed increased levels of  $A\beta_{1-40}$  in the hippocampi ( $p = 0.004$ ; **figure 7C**) and  
25  
26 cortices ( $p = 0.001$ ). However, chronic administration of anti-IL17 did not reduce the levels of this  
27  
28 peptide in the TS or CO mice in either the hippocampus or the cortex.  
29  
30  
31

### 32 33 34 **3.6. Side effects: chronic treatment with anti-IL17 did not affect the sensorimotor abilities,** 35 36 **spontaneous activity, motor coordination or anxiety levels of the TS or CO mice** 37 38 39

40  
41 In the different behavioral tests performed to assess the putative side effects of anti-IL17, the  
42  
43 IgG1-C- and saline-treated animals achieved similar scores. Because IgG1-C administration did  
44  
45 not modify the behaviors of the animals in any test (data not shown), we have only presented the  
46  
47 performance data of the IgG1-C-treated mice and anti-IL17-treated mice.  
48  
49  
50

51  
52 In the *sensorimotor test battery*, the aged TS mice demonstrated impaired equilibrium and motor  
53  
54 coordination (latency to fall and number of crossings) in the coat hanger test. However, chronic  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 anti-IL17 administration did not affect equilibrium or the different reflexes of the motor abilities of  
2 the TS or CO mice (**Table 2**).

3  
4  
5  
6  
7 In addition, the different groups of mice did not differ in the *spontaneous activity* performed in  
8 their home cage during a complete 24-hour cycle (dark hours: 'genotype', p=0.22; 'treatment',  
9 p=0.38; and 'genotype x treatment', p=0.96; light hours: 'genotype', p=0.61; 'treatment', p=0.19;  
10 and 'genotype x treatment', p=0.54; **figure 8A**).

11  
12  
13  
14  
15  
16  
17  
18  
19 *Motor coordination in the Rotarod* was not affected by the genotype or treatment, as  
20 demonstrated by the similar latencies in falling from this apparatus that were displayed by the four  
21 groups of mice during the different constant speeds (20 r.p.m.: 'genotype', p=0.60; 'treatment',  
22  $F_{(1,48)}=1.11$ , p=0.29; and 'genotype x treatment', p=0.71; 40 r.p.m.: 'genotype', p=0.15;  
23 'treatment', p=0.55; and 'genotype x treatment', p=0.71; **figure 8B**) or during the acceleration  
24 cycle ('genotype', p=0.35; 'treatment', p=0.59; and 'genotype x treatment', p=0.77; **figure 8C**).

25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36 Anti-IL17 treatment did not affect *locomotor activity* or *anxiety* in the TS or CO mice. In the *open*  
37 *field test*, there were no significant differences in the total distances traveled by the four groups of  
38 mice ('genotype', p=0.095; 'treatment', p=0.91; and 'genotype x treatment', p=0.60; **figure 9A**).

39  
40  
41  
42  
43 The apparent anxiety levels were not different between the TS and CO mice under both  
44 treatments since these mice traveled similar distances in the center (ANOVA: 'genotype', p=0.08;  
45 'treatment', p=0.63; and 'genotype x treatment', p=0.40) and periphery of the maze ('genotype',  
46 p=0.15; 'treatment', p=0.96; and 'genotype x treatment':, p=0.75; **figure 9A**). The four groups of  
47 mice also displayed similar amounts of vertical activity, namely, attempts to escape from the  
48 maze ('genotype', p=0.62; 'treatment', p=0.48; and 'genotype x treatment', p=0.56; **figure 9B**).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Finally, in the *plus maze test*, the anxiety displayed by the animals was not modified by the administration of anti-IL17. The TS and CO mice treated with the vehicle or antibody performed similar numbers of entries into the open arms ('genotype',  $p=0.20$ ; 'treatment',  $p=0.53$ ; 'genotype x treatment',  $p=0.19$ ), performed similar total numbers of entries ('genotype',  $p=0.55$ ; 'treatment',  $p=0.65$ ; and 'genotype x treatment',  $p=0.37$ ; **figure 10A**), had similar durations of initial freezing times ('genotype',  $p=0.18$ ; 'treatment',  $p=0.74$ ; and 'genotype x treatment',  $p=0.50$ ; **figure 10B**) and had similar percentages of time spent in the open arms ('genotype',  $p=0.10$ ; 'treatment',  $p=0.23$ ; and 'genotype x treatment',  $p=0.52$ ; **figure 10C**). These results indicated that the anxiety displayed by the animals was not affected by the genotypes of the animals or the treatment received.

#### 4. DISCUSSION

1  
2  
3 Neuroinflammation contributes to the progression of cognitive decline in patients with AD and DS.

4  
5 In DS, neuroinflammation is an early event that precipitates and aggravates AD neuropathology  
6  
7 and cognitive decline (Wilcock and Griffin, 2013; Wenk et al., 2000; Griffin et al., 1989).  
8  
9

10 Accordingly, in this study, we observed the increased expression of several pro-inflammatory  
11  
12 mediators in the hippocampi of 12-month-old TS mice. Among these mediators, we focused our  
13  
14 attention on IL17 due to its role in mediating brain damage through its potent pro-inflammatory  
15  
16 actions (Meares et al., 2012; Zimmerman et al., 2013). Here, using an anti-IL17 mAb that crosses  
17  
18 the blood brain barrier (St-Amour et al., 2013), we report that the chronic inhibition of this cytokine  
19  
20 reduced neuroinflammation, ameliorated cognitive and neuromorphological alterations and  
21  
22 alleviated AD-like neurodegenerative features in the TS mouse model of DS. In particular, the  
23  
24 anti-IL17 treatment ameliorated the deficits in hippocampal cell proliferation and survival,  
25  
26 cholinergic neurodegeneration and cellular senescence. The anti-IL17 treatment also reduced  
27  
28 hippocampal APP and A $\beta$ <sub>1-42</sub> peptide levels in the TS mice.  
29  
30  
31  
32  
33

34  
35 The altered expression of pro-inflammatory cytokines and chemokines plays an important role in  
36  
37 the appearance of AD neuropathological changes associated with the progression of cognitive  
38  
39 decline in DS (Carta et al., 2002). We have demonstrated that TS mice present an altered  
40  
41 hippocampal inflammatory milieu characterized by increased levels of pro-inflammatory mediators  
42  
43 IL17A, IL1 $\beta$ , IFN $\gamma$  G-CSF, MIP3 $\alpha$ , IL3 and IL15, which may play important roles in the  
44  
45 progression of AD neuropathology and cognitive decline of aged TS mice. Few studies have  
46  
47 evaluated cytokine and chemokine alterations in the brains of DS mouse models, and these  
48  
49 studies have reported controversial results. Although Lockrow et al. (2011) reported increased  
50  
51 levels of IL1 $\beta$  in the hippocampi of TS mice, Roberson et al. (2012) found that the expression  
52  
53 levels of this pro-inflammatory cytokine were reduced in these animals. Furthermore, some of the  
54  
55 cytokines and chemokines that we found to be increased in the TS hippocampi of the present  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 study were either unchanged (IL15 or IFN $\gamma$ ) or undetectable (G-CSF and IL17) in the Robertson  
2 et al. (2012) study. However, consistent with our results, Hallan et al. (2000) observed increased  
3 levels of IFN $\gamma$  in the whole-brain homogenates of a Ts16 model of DS. These discrepancies may  
4 be due to different methods used to quantify these cytokines, the age of the animals or the  
5 experimental manipulations preceding the assessments reported in the different studies.  
6  
7

8  
9  
10  
11  
12 IL17 plays an important role in inflammatory brain disorders, as demonstrated by the increased  
13 levels of this cytokine in multiple sclerosis (Tzartos et al., 2008), infectious CNS diseases (Guiton  
14 et al., 2010) and stroke (Shichita et al., 2009; Li et al., 2005). The role of IL17 in mediating brain  
15 damage in neuroinflammatory processes has been associated with its ability to induce the  
16 expression of other pro-inflammatory chemokines and cytokines (Zimmerman et al., 2013;  
17 Meares et al., 2012; Korn et al., 2009). IL17 can work synergistically with IL1 $\beta$  and IFN $\gamma$  to  
18 increase the production of other pro-inflammatory mediators (Onishi and Gaffen, 2010). In  
19 addition, IL1 $\beta$  and IL15, whose levels are increased in the hippocampi of TS mice, can also  
20 induce the expression of IL17 (Sutton et al., 2006; Ferretti et al., 2003) and potentiate its pro-  
21 inflammatory effects (Flores-García et al., 2012; Ferretti et al., 2003), suggesting the existence of  
22 positive feedback circuits induced by IL17 and other cytokines (Flores-García et al., 2012). In this  
23 regard, we show herein that the enhanced expression of IFN $\gamma$ , IL1 $\beta$ , IL15, MIP3 $\alpha$ , G-CSF and  
24 IL17A observed in the hippocampi of the TS mice is significantly reduced by the chronic  
25 administration of an anti-IL17A mAb.  
26  
27

28  
29  
30  
31  
32 Consistent with the cognitive alterations found in DS and AD and in the mouse models of these  
33 conditions (see Rueda and Martínez-Cué, 2015; Rueda et al., 2012; Bartesaghi et al., 2011), in  
34 the present study, aged TS mice displayed profound deficits in their abilities to learn a spatial  
35 task. Treatment with an anti-IL17A mAb induces protective effects in diverse murine models of  
36 degenerative and autoimmune neurological diseases, such as ischemic stroke (Gelderblom et al.,  
37 2012) and experimental autoimmune encephalomyelitis (EAE), the most extensively studied  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 experimental model of multiple sclerosis (Uvtenhove and Van Snick, 2006). Consistent with  
2 these findings, our present study extended these observations to TS mice. Chronic administration  
3 of anti-IL17 ameliorated the spatial learning deficits of TS mice. This treatment also improved the  
4 performance of the CO mice in the same test. This beneficial effect is likely due to an  
5 enhancement in the cognitive abilities and not to an improvement in the motor or motivational  
6 abilities of the animals since the different groups of mice did not differ in their latency to reach the  
7 visible platform during the cued trials or in their swimming speed. Further support for this specific  
8 pro-cognitive effect of anti-IL17 administration comes from the finding that the administration of  
9 the IgG1-C isotype control did not induce an effect on the performances of the TS or CO animals  
10 in the water maze.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 In addition, the administration of anti-IL17 to the TS or CO mice did not induce behavioral side  
26 effects since the sensorimotor abilities, spontaneous activity, motor coordination and anxiety  
27 levels of the animals remained unaffected.  
28  
29  
30  
31  
32

33 Several non-mutually exclusive mechanisms may account for the beneficial effect of the anti-IL17  
34 treatment on the cognitive abilities of TS mice. Increased neuroinflammation in DS brains  
35 appears to be mainly mediated by the exacerbation of macrophage activation state 1 (M1) cells  
36 due to the triplication of some critical inflammatory-associated genes, including *RCAN1*, *CXADR*,  
37 *ADAMTS1*, *ADAMTS5*, *TIAM1*, and *IFNGR2* (Wilcock and Griffin, 2013; Wilcock, 2012; Martin et  
38 al., 2012). M1 macrophages possess potent pro-inflammatory properties, which are characterized  
39 by the release of reactive oxygen species (ROS) and several cytokines, mainly comprising IFN $\gamma$   
40 and TNF $\alpha$  but also IL1 $\beta$ , IL6 and IL12. The expression of several of these M1 mediators (e.g.,  
41 IL1 $\beta$  and IFN $\gamma$ ) is increased in the hippocampi of TS mice and decreases after anti-IL17  
42 administration. These findings suggest that the inflammatory profile found in the brains of TS  
43 mice can be associated with an increased M1 inflammatory response, as occurs in DS brains,  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 and that the anti-IL17 treatment may exert its therapeutic activity by modulating M1 macrophage  
2 polarization and/or activity.  
3

4  
5 Neuroinflammation is one of the most potent inducers of the increased levels of APP and A $\beta$  in  
6  
7 AD and DS. An excess of cytokine production, especially of IL1 $\beta$ , leads to the overexpression of  
8  
9 APP (Liu et al., 2011; Sheng et al., 1996) and accelerated formation of A $\beta$  plaques (Sheng et al.,  
10  
11 1997). Furthermore, the high production of other cytokines, such as IFN $\gamma$ , may also act in  
12  
13 combination with IL1 $\beta$  to increase the production of intracellular A $\beta$  in neurons and astrocytes  
14  
15 (Blasko et al., 2001). In addition, in AD, activated astrocytes and microglia are located around  
16  
17 amyloid plaques, which suggests that A $\beta$  activates this inflammatory pathway. Thus, a positive  
18  
19 feedback mechanism likely exists between pro-inflammatory cytokine production, the A $\beta$  burden  
20  
21 and the APP level (Wilcock and Griffin, 2013). In DS, the overexpression of the triplicated gene  
22  
23 *APP* is accompanied by an increase in IL1 $\beta$  levels and in microglial and astrocytic activation, with  
24  
25 increases in APP expression (Wilcock and Griffin, 2013; Sheng et al., 1996; Li et al., 1998). Such  
26  
27 glial activation and cytokine overexpression in DS occurs years before the appearance of A $\beta$   
28  
29 plaques (Wisniewski et al., 1985). Although the TS mouse contains an extra copy of the *App*  
30  
31 gene, these mice do not develop amyloid plaques; however, these mice display increased  
32  
33 expression of full-length APP mRNA and protein in the cortex and hippocampus (Corrales et al.,  
34  
35 2013; Rueda et al., 2010; Choi et al., 2009; Seo et al., 2005). Consistent with the enhanced *App*  
36  
37 levels found in this study, the present study and numerous studies from other laboratories have  
38  
39 demonstrated that the hippocampal and cortical levels of both peptides, namely, A $\beta$ <sub>1-40</sub> and A $\beta$ <sub>1-  
40  
41 42</sub>, are increased in TS mice (Corrales et al., 2013; Netzer et al., 2010). These alterations may  
42  
43 contribute to neuronal and cognitive degeneration in these animals because of the role of these  
44  
45 peptides in the degeneration of cholinergic neurons. In fact, in normal rodents, cognitive  
46  
47 alterations can be induced by intracerebral or intracerebroventricular infusion of A $\beta$  peptides into  
48  
49 the brain (for review, see Lawlor and Young, 2010), and in TS mice, chronic treatment with A $\beta$ -  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 lowering drugs restores their cognitive abilities (Netzer et al., 2010). Our present results are  
2 consistent with roles of inflammatory cytokines, particularly IL17A, in the enhanced expression of  
3 APP in the brains of TS mice. Indeed, the reduced expression of pro-inflammatory cytokines after  
4 the administration of anti-IL17 normalized the APP levels in the TS mice and the A $\beta$ <sub>1-42</sub> levels in  
5 the hippocampi of both the TS and CO mice. Because of the role of the A $\beta$  load on cognitive  
6 deficits and because of the interrelation between A $\beta$ , App and pro-inflammatory cytokine  
7 production, the enhanced cognitive abilities of the TS mice after anti-IL17 administration might be  
8 mediated by the ability of anti-IL17 to reduce these cytokines and normalize APP and A $\beta$  levels.  
9 However, the cognitive improvement in the anti-IL17-treated TS animals was only partial,  
10 suggesting that other altered mechanisms implicated in their memory impairments are not  
11 rescued by this treatment.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 Another consequence of neuroinflammation is the exacerbation of neurodegeneration, particularly  
28 of basal forebrain-cholinergic neurons (BFCN), in AD and DS brains, (Griffin et al., 1989; Wenk et  
29 al., 2000; Wilcock and Griffin, 2013). In TS mice, several studies have demonstrated an age-  
30 dependent decline in BFCN markers that correlates with cognitive deterioration (Granhholm et al.,  
31 2000; Hunter et al., 2004; Seo and Isacson, 2005). TNF $\alpha$  produces retrograde degeneration of  
32 BFCNs in TS mice. In addition, IL1 $\beta$  induces the synthesis and activity of acetylcholinesterase,  
33 thus favoring the breakdown of acetylcholine (Li et al., 2000), which plays a fundamental role in  
34 learning and memory (Levin et al., 1994). Moreover, BFCN degeneration activates inflammatory  
35 pathways, and thus, neurodegeneration and neuroinflammation also have interactive and  
36 escalating effects in these animals. In the present study, we found that 12-month-old vehicle-  
37 treated TS mice showed a reduced density of BFCNs. Treatment with anti-IL17 attenuated this  
38 neuronal loss, although the effect was not very pronounced. These results suggest that reducing  
39 neuroinflammation is not sufficient to totally prevent cholinergic neurodegeneration in TS animals.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

In human astrocytes (Bhat et al., 2012) and mouse neurons (Jurk et al., 2012), cells with a senescent phenotype, a process that is characterized by permanent arrest of cell proliferation (Vidal et al., 2012), may contribute to the dysfunction of the aging brain. Cell senescence is mainly induced by enhanced oxidative stress (Zhou et al., 2015; Rodríguez-Sureda et al., 2015; He et al., 2013). Fibroblasts with trisomy 21 present signs of premature cell senescence that is secondary to increased oxidative damage (Rodríguez-Sureda et al., 2015). Consistent with these findings, we have recently demonstrated that the hippocampus of adult TS mice show greater amounts of oxidative damage and increased densities of cells with a senescent phenotype (Parisotto et al., 2016; García-Cerro et al., 2017). IL17A releases ROS (Huppert et al., 2010), and thus, the blockade of IL17A can reduce oxidative stress, preventing the cells from acquiring a senescent phenotype. However, in the present study, the anti-IL17 treatment only partially attenuated the increased density of hippocampal cells with a senescent phenotype in the TS mice. Therefore, this effect cannot account for the pro-cognitive effect of the chronic administration of this antibody.

Neuroinflammation also affects adult neurogenesis and has both detrimental and beneficial consequences, which can result in the enhancement and/or inhibition of neurogenesis (see Llorens et al., 2014). In particular, increased levels of IL1 $\beta$  or IFN $\gamma$ , which are elevated in the hippocampi of TS mice, decrease proliferation, survival and neuronal differentiation (Fuster-Matanzo et al., 2013; Villeda et al., 2011). Therefore, the enhanced levels of these pro-inflammatory mediators might also be partially responsible for the altered neurogenesis found in the TS mouse. However, the reduced expression of IL1 $\beta$  and IFN $\gamma$  after the anti-IL17 treatment did not correlate with the effect of this antibody on adult neurogenesis because the impaired proliferation found in the TS mice was not completely rescued after anti-IL17 administration. In addition, this treatment did not have a profound effect on the survival of hippocampal granular



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

cells. Once again, only a slight recovery from the hypocellularity found in the TS animals was evident after anti-IL17 administration.

The results presented here suggest that IL-17A-mediated neuroinflammation is involved in several AD phenotypes in TS mice and provides a new therapeutic target toward reducing these pathological characteristics. Furthermore, the fact that the treatment with anti-IL17A mAb ameliorates some of these altered phenotypes in this model of DS offers new perspectives for the therapy of AD and DS by using anti-pro-inflammatory cytokine antibodies. However, many of the putative mechanisms underlying the cognitive abilities of the TS animals were only partially affected by chronic anti-IL17A administration, and the improvements induced by this treatment in terms of the learning and memory deficits of the TS mice were only partial. Therefore, future studies should explore the efficacies of other antibodies targeting other pro-inflammatory cytokines, such as IL1 $\beta$ .

### **Acknowledgements**

This study was supported by the Jerome Lejeune Foundation, Fundación Tatiana Pérez de Guzmán el Bueno, the Spanish Ministry of Economy and Competitiveness (PSI-2016-76194-R, SAF2014-55088-R, SAF2016-75195-R, AEI/FEDER, EU) and Luchamos por la Vida Foundation.

## FIGURE CAPTIONS

1  
2  
3 **Figure 1.** Hippocampal inflammatory milieu of the different groups of mice treated with saline,  
4 IgG1-C or anti-IL17. Mouse cytokine protein arrays were performed on two identical independent  
5 groups comprising 5 mice from each experimental group. The figure shows only the pro-  
6 inflammatory mediators with statistically significant differences between the experimental  
7 conditions. The values correspond to the % change with respect to the vehicle control group. \*:  
8 p<0.05; \*\*: p<0.01, TS vs. CO; Bonferroni tests after significance by ANOVA.  
9

10  
11 **Figure 2.** Mean  $\pm$  S.E.M. of the latency to reach the platform (A-C), the time spent in the  
12 periphery of the pool (D-F) during the 8 acquisition sessions and the latency to reach the platform  
13 during the cued sessions (G) in the Morris water maze of the TS and CO mice treated with saline,  
14 IgG1-C or anti-IL17. \*: p<0.05, \*\*: p<0.01, \*\*\*: p<0.001, TS vs. CO; #: p<0.05, ##: p<0.01, IgG1-C  
15 vs. anti-IL17; Bonferroni tests after significance by ANOVA.  
16  
17

18  
19 **Figure 3.** Representative images of Ki67+ cells (green) in the hippocampi of the TS and CO mice  
20 (A) and the mean  $\pm$  S.E.M. of the density of Ki67+ cells (B) in the subgranular zone of the  
21 hippocampi of the TS and CO IgG1-C- and anti-IL17-treated mice. \*\*: p<0.01, TS vs. CO;  
22 Bonferroni tests after significance by ANOVA.  
23  
24

25  
26 **Figure 4.** Representative images of DAPI+ cells (A) and the mean  $\pm$  S.E.M. of the density of  
27 DAPI+ cells (B) in the DGs of the TS and CO IgG1-C- and anti-IL17-treated mice. \*\*\*: p<0.001,  
28 TS vs. CO; Bonferroni tests after significance by ANOVA.  
29  
30

31  
32 **Figure 5.** Representative images of ChAT immunostaining in the septum (A) and the mean  $\pm$   
33 S.E.M. of the density of ChAT+ cells (B) in the medial septum of the IgG1-C- and anti-IL17-  
34 treated CO and TS mice. \*: p<0.05, TS vs. CO; Bonferroni tests after significance by ANOVA.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Figure 6.** Representative images of cells with a senescent phenotype (A) and the mean  $\pm$  S.E.M. of the density of  $\beta$ -galactosidase+ cells (B) in the hippocampi of TS and CO IgG1-C- and anti-IL-17-treated mice. \*\*:  $p < 0.01$ , TS vs. CO; Bonferroni tests after significance by ANOVA.

**Figure 7.** Western blot analysis of APP levels (differences are expressed relative to the values of the vehicle-treated CO mice, defined as 100%) (A), ELISA analysis of the  $A\beta_{1-42}$  (B) and  $A\beta_{1-40}$  (C) levels in the cortices and hippocampi of the vehicle- and anti-IL17-treated TS and CO mice. \*:  $p < 0.05$ , \*\*:  $p < 0.001$ , TS vs. CO; #:  $p < 0.05$ , ##:  $p < 0.01$ , IgG1-C vs. anti-IL17; Bonferroni tests after significance by ANOVA.

**Figure 8.** Mean  $\pm$  S.E.M. of the average spontaneous activity of the TS and CO mice treated with IgG1-C or anti-IL-17 during 24 hours of the dark-light cycle (A), of the latency to fall from the rotarod at different constant speeds (B) and during the acceleration cycle (C).

**Figure 9.** Mean  $\pm$  S.E.M. of the distance traveled in the center and periphery, of the total distance traveled (A) and of the number of rearings performed by the TS and CO mice treated with IgG1-C or anti-IL-17 in the open field test.

**Figure 10.** Mean  $\pm$  S.E.M. of the number of entries into the open and closed arms (A), the initial freezing time (B) and the percentage of time spent in the open arms (C) by the TS and CO mice treated with IgG1-C or anti-IL17 in the Plus maze test. \*:  $p < 0.05$ , TS vs. CO; Bonferroni tests after significance by ANOVA.

**Table 1** MANOVA *p* values (genotype x treatment) for inflammatory mediators in the hippocampus of the six animal groups.

Inflammatory Mediator	MANOVA GENOTYPE; F <sub>(1,6)</sub>	MANOVA TREATMENT			
		IgG1-C; F <sub>(1,4)</sub>		Anti-IL17A; F <sub>(1,4)</sub>	
		Treatment	Genotype x treatment	Treatment	Genotype x treatment
IL17A	<b>p=0.026</b>	p=0.98	p=0.65	<b>p=0.017</b>	p=0.15
IFN $\gamma$	<b>p=0.047</b>	p=0.36	p=0.99	<b>p=0.033</b>	p=0.39
MIP3A	<b>p=0.036</b>	p=0.85	p=0.73	<b>p=0.007</b>	p=0.46
IL-1 $\beta$	<b>p=0.04</b>	p=0.95	p=0.67	<b>p=0.039</b>	p=0.74
IL-3	<b>p=0.012</b>	p=0.50	p=0.02	p=0.57	p=0.66
IL-15	<b>p=0.004</b>	p=0.98	p=0.28	<b>p=0.001</b>	<b>p=0.003</b>
G-CSF	<b>p=0.002</b>	p=0.91	p=0.068	<b>p=0.023</b>	p=0.72
CXCL12	<b>p=0.012</b>	p=0.19	p=0.53	p=0.29	p=0.86

**Table 2.** Score of vehicle- and anti-IL17-treated TS and CO mice in the sensorimotor test battery

	IgG1-C		anti- IL17		F <sub>(1,48)</sub>		
	CO	TS	CO	TS	Genotype	Treatment	Genotype x treatment
<b>Vision</b>	2.41 ± 0.14	2.30 ± 0.13	2.58 ± 0.14	2.42 ± 0.13	0.86, p=0.35	1.02, p=0.31	0.02, p=0.87
<b>Startle reflex</b>	1.00 ± 0.12	1.53 ± 0.21*	1.16 ± 0.11	1.14 ± 0.36	3.13, p=0.08	0.32, p=0.43	3.74, p=0.06
<b>Righting reflex</b>	3.00 ± 0.00	3.00 ± 0.00	3.00 ± 0.00	3.00 ± 0.00			
<b>Grip strength</b>	2.66 ± 0.22	2.07 ± 0.23	2.25 ± 0.27	2.00 ± 0.23	2.86, p=0.09	0.86, p=0.35	0.82, p=0.37
<b>Wooden bar</b>	2.25 ± 0.17	2.00 ± 0.00	2.66 ± 0.25	1.92 ± 0.07*	<b>10.52</b> <b>p=0.002</b>	1.28, p=0.26	2.56, p=0.11
<b>Equilibrium</b>	0.33 ± 0.22	0.23 ± 0.23	0.25 ± 0.25	0.14 ± 0.09	0.26, p=0.61	0.17, p=0.67	0.00, p=0.99
<b>Latency, wooden bar</b>	20.00± 0.00	20.00 ± 0.00	20.00± 0.00	19.46 ± 0.53	0.82, p=0.37	0.82, p=0.37	0.82, p=0.37
<b>Latency, aluminum bar</b>	6.50 ± 1.08	4.61 ± 0.81	7.16 ± 1.94	6.21 ± 1.44	1.05, p=0.30	0.67, p=0.41	0.11, p=0.73
<b>Prehensile reflex</b>	2.66 ± 0.25	2.23 ± 0.23	2.66 ± 0.14	2.42 ± 0.20	2.50, p=0.12	0.21, p=0.64	0.21, p=0.64
<b>Traction capacity</b>	1.5 ± 0.59	1.00 ± 0.35	1.50 ± 0.43	1.85 ± 0.49	0.02 p=0.88	0.80, p=0.37	0.37, p=0.93
<b>Latency to fall</b>	26.91 ± 6.43	13.61 ± 5.15	34.91 ± 7.16	16.57 ± 5.96	<b>6.53,</b> <b>p=0.01</b>	0.78, p=0.38	0.16, p=0.68
<b>Coat hanger</b>	3.83 ± 0.75	1.69 ± 0.63*	4.50 ± 0.92	2.64 ± 0.76	<b>6.65,</b> <b>p=0.013</b>	1.08, p=0.30	0.03, p=0.85
<b>Latency of arrival</b>	33.00 ± 6.28	37.53 ± 7.62	25.33 ± 6.23	35.28 ± 6.76	1.12 p=0.29	0.52, p=0.47	0.15, p=0.69

## References

- 1 Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and  
2 modulation by apolipoprotein E. *Nature*. 1997; 388: 878–881.
- 3  
4 Bartesaghi R, Guidi S, Ciani E. Is it possible to improve neurodevelopmental abnormalities in  
5 Down syndrome? *Rev Neurosci*. 2011; 22: 419-55.
- 6  
7 Beringer A, Noack M, Miossec P. 2016. IL-17 in Chronic Inflammation: From Discovery to  
8 Targeting. *Trends Mol Med*. 22:230-41.
- 9  
10 Bhat R, Crowe EP, Bitto A, et al. Astrocyte senescence as a component of Alzheimer's disease.  
11 *PLoS One*. 2012; 7:e45069.
- 12  
13 Blasko I, Ransmayr G, Veerhuis R, Eikelenboom P, Grubeck-Loebenstien B. 2001. Does IFN $\gamma$   
14 play a role in neurodegeneration? *Journal of Neuroimmunology* 116 : 1–4.
- 15  
16 Blurton-Jones M, Laferla FM. Pathways by which Abeta facilitates tau pathology. *Curr Alzheimer*  
17 *Res*. 2006; 3:437-48.
- 18  
19 Bowes C, Li T, Frankel WN, Danciger M, Coffin JM, Applebury ML, Farber DB. Localization of a  
20 retroviral element within the rd gene coding for the beta subunit of cGMP phosphodiesterase.  
21 *Proc Natl Acad Sci USA*. 1993; 90: 2955-2959.
- 22  
23 Carta MG, Serra P, Ghiani A, Manca E, Hardoy MC, Del Giacco GS, Diaz G, Carpiniello B,  
24 Manconi PE. 2002. Chemokines and pro-inflammatory cytokines in Down's syndrome: an early  
25 marker for Alzheimer-type dementia? *Psychother Psychosom* 2002; 71:233-6.
- 26  
27 Cenini G, Dowling AL, Beckett TL, Barone E, Mancuso C, Murphy MP, et al. Association between  
28 frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.  
29 *Biochim Biophys Acta*. 2012; 1822: 130-8.
- 30  
31 Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, Games D,  
32 Freedman SB, Morris RG. A learning deficit related to age and beta-amyloid plaques in a mouse  
33 model of Alzheimer's disease. *Nature*. 2000; 408: 975-979.
- 34  
35 Chong Y. Effect of a carboxy-terminal fragment of the Alzheimer's amyloid precursor protein on  
36 expression of proinflammatory cytokines in rat glial cells. *Life Sci*. 1997; 61:2323-33.
- 37  
38 Choi JH, Berger JD, Mazzella MJ, Morales-Corraliza J, Cataldo AM, Nixon RA, et al. Age-  
39 dependent dysregulation of brain amyloid precursor protein in the Ts65Dn Down syndrome  
40 mouse model. *J Neurochem*. 2009; 110:1818-27.
- 41  
42 Corrales A, Vidal R, García S, Vidal V, Martínez P, García E, et al. Chronic melatonin treatment  
43 rescues electrophysiological and neuromorphological deficits in a mouse model of Down  
44 syndrome. *J Pineal Res*. 2014; 56 :51-61.
- 45  
46 Corrales A, Martínez P, García S, Vidal V, García E, Flórez J, et al. Long-term oral administration  
47 of melatonin improves spatial learning and memory and protects against cholinergic degeneration  
48 in middle-aged Ts65Dn mice, a model of Down syndrome. *J Pineal Res*. 2013; 54: 346-58.
- 49  
50 Dallenbach K, Maurer P, Röhn T, Zabel F, Kopf M, Bachmann MF. Protective effect of a  
51 germline, IL-17-neutralizing antibody in murine models of autoimmune inflammatory disease. *Eur*  
52 *J Immunol*. 2015; 45: 1238-47.
- 53  
54 Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C. Microglia and cytokines in neurological  
55 disease, with special reference to AIDS and Alzheimer's disease. *Glia*. 1993; 7: 75–83.
- 56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJM, van Gool WA, Hoozemans JJM. The  
2 significance of neuroinflammation in understanding Alzheimer's disease. *J Neural Transm.* 2006;  
3 113:1685–95.

4 Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A. IL- 17, produced by lymphocytes and  
5 neutrophils, is necessary for lipopolysaccharide- induced airway neutrophilia: IL-15 as a possible  
6 trigger. *J Immunol.* 2003; 170: 2106–2112.

7  
8 Flores-García Y, Talamás-Rohana P. Interleucina 17, funciones biológicas y su receptor. *REB.*  
9 2005; 31: 3-9.

10  
11 Fuster-Matanzo A, Llorens-Martín M, Hernández F, Avila J. 2013. Role of neuroinflammation in  
12 adult neurogenesis and Alzheimer disease: therapeutic approaches. *Mediators*  
13 *Inflamm;*2013:260925.

14  
15 García-Cerro S, Rueda N, Vidal V, Lantigua S, Martínez-Cué C. Normalizing the gene dosage of  
16 Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.  
17 *Neurobiol Dis.* 2017 Oct;106:76-88. doi: 0.1016/j.nbd.2017.06.010. Epub 2017 Jun 21.

18  
19 Gelderblom M, Weymar A, Bernreuther C, Velden J, Arunachalam P, Steinbach K, Orthey E,  
20 Arumugam TV, Leyboldt F, Simova O, Thom V, Friese MA, Prinz I, Hölscher C, Glatzel M, Korn  
21 T, Gerloff C, Tolosa E, Magnus T. Neutralization of the IL-17 axis diminishes neutrophil invasion  
22 and protects from ischemic stroke. *Blood.* 2012; 120: 3793-802.

23  
24 Gitter BD, Cox LM, Rydel RE, May PC. Amyloid beta peptide potentiates cytokine secretion by  
25 interleukin-1 beta-activated human astrocytoma cells. *Proc Natl Acad Sci U S A.* 1995; 92:10738-  
26 41.

27  
28 Granholm AC, Sanders LA, Crnic LS. Loss of cholinergic phenotype in basal forebrain coincides  
29 with cognitive decline in a mouse model of Down's syndrome. *Exp Neurol.* 2000; 161:647-63.

30  
31 Griffin WS. Inflammation and neurodegenerative diseases. *Am J Clin Nutr.* 2006; 83:470S-4S.

32  
33 Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al. Brain interleukin 1 and S-  
34 100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. *Proc Natl Acad Sci*  
35 *U S A.* 1989; 86:7611-5.

36  
37 Guerreiro R, Bras J, Hardy J. Snapshot: genetics of Alzheimer's disease. *Cell.* 2013; 155: 968–  
38 e961.

39  
40 Guiton R, Vasseur V, Charron S, Arias MT, Van Langendonck N, et al. Interleukin 17 Receptor  
41 Signaling Is Deleterious during *Toxoplasma gondii* Infection in Susceptible BL6 Mice. *J Infect Dis.*  
42 2010; 202:427–435.

43  
44 Hallam DM, Capps NL, Travelstead AL, Brewer GJ, Maroun LE. Evidence for an interferon-  
45 related inflammatory reaction in the trisomy 16 mouse brain leading to caspase-1-mediated  
46 neuronal apoptosis. *J Neuroimmunol.* 2000; 110:66-75.

47  
48 Hardy J. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? *Curr*  
49 *Alzheimer Res.* 2006;3(1):71-3.

50  
51 Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science.* 1992;  
52 256:184-5.

53  
54 Haydar TF, Reeves RH. Trisomy 21 and early brain development. *Trends Neurosci.*  
55 2012;35(2):81-91.

1 He N, Jin WL, Lok KH, et al. Amyloid- $\beta$ (1-42) oligomer accelerates senescence in adult  
2 hippocampal neural stem/progenitor cells via formylpeptide receptor 2. *Cell Death Dis.* 2013;  
3 4:e924.

4 Ho GJ, Drego R, Hakimian E, Masliah E. Mechanisms of cell signaling and inflammation in  
5 Alzheimer's disease. *Current Drug Targets.* 2005; 4: 247–256.

6  
7 Hunter CL, Bachman D, Granholm AC. Minocycline prevents cholinergic loss in a mouse model  
8 of Down's syndrome. *Ann Neurol.* 2004; 56:675-88.

9  
10 Huppert J, Closhen D, Croxford A, White R, Kulig P, et al. Cellular Mechanisms of IL-17-Induced  
11 Blood-Brain Barrier Disruption. *FASEB J.*2010; 24:1023–1034.

12  
13 Jurk D, Wang C, Miwa S, et al. Postmitotic neurons develop a p21-dependent senescence-like  
14 phenotype driven by a DNA damage response. *Aging Cell.* 2012; 11: 996–1004.

15  
16 Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. *Annu Rev Immunol.* 2009; 27:  
17 485–517.

18  
19 Lawlor P, Young D. Ab infusion and related models of Alzheimer dementia. In: De Deyn P, Van  
20 Dam D, editors. *Animal Models of Dementia.* 2010. New York: Springer Science and Business  
21 Media; p. 347-70.

22  
23 Levin ED, Briggs SJ, Christopher NC, Auman JT. Working memory performance and cholinergic  
24 effects in the ventral tegmental area and substantia nigra. *Brain Res.* 1994; 657:165–170.

25  
26 Li G-Z, Zhong D, Yang L-M, Sun B, Zhong Z-H, et al. Expression of Interleukin-17 in Ischemic  
27 Brain Tissue. *Scand J Immunol.* 2005; 62:481–486.

28  
29 Li Y, Liu L, Kang J, Sheng JG, Barger SW, Mrak RE, Griffin WS. Neuronal-glia interactions  
30 mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression.  
31 *J Neurosci.* 2000; 20:149–155.

32  
33 Li Y, Wang J, Sheng JG, Liu L, Barger SW, Jones RA, Van Eldik LJ, Mrak RE, Griffin WS. S100  
34 beta increases levels of beta-amyloid precursor protein and its encoding mRNA in rat neuronal  
35 cultures. *J Neurochem.* 1998; 71:1421–1428.

36  
37 Liu L, Aboud O, Jones RA, Mrak RE, Griffin WS, Barger SW. Apolipoprotein E expression is  
38 elevated by interleukin 1 and other interleukin 1-induced factors. *J Neuroinflammation.* 2011;  
39 8:175.

40  
41 Liu DP, Schmidt C, Billings T, Davisson MT. A quantitative PCR genotyping assay for the Ts65Dn  
42 mouse model of Down syndrome. *Biotechniques.* 2003; 35: 1170-1174.

43  
44 Llorens-Martín M, Jurado-Arjona J, Fuster-Matanzo A, Hernández F, Rábano A, Ávila J.  
45 Peripherally triggered and GSK-3B driven brain inflammation differentially skew adult  
46 hippocampal neurogenesis, behavioral pattern separation and microglial activation in response to  
47 ibuprofen. *Trans. Psychiatry.* 2014; 4: e463.

48  
49 Llorens-Martín MV, Torres-Alemán I, Trejo JL (2006) Pronounced individual variation in the  
50 response to the stimulatory action of exercise on immature hippocampal neurons. *Hippocampus*  
51 16: 480-490.

52  
53 Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC. Effects of long-term memantine on  
54 memory and neuropathology in Ts65Dn mice, a model for Down syndrome. *Behav Brain Res.*  
55 2011; 221: 610-22.

56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 Lockrow J, Prakasam A, Huang P, Bimonte-Nelson H, Sambamurti K, Granholm AC. Cholinergic  
2 degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. *Exp*  
3 *Neurol.* 2009; 216: 278-89.

4 Lott IT. Neurological phenotypes for Down syndrome across the life span. *Prog Brain Res.*  
5 2012;197:101-21.

6  
7 Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals  
8 with Down's syndrome. *Lancet Neurol.* 2010;9(6):623-33.

9  
10 Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol  
11 reagent. *J Biol Chem.* 1951; 193: 265-275.

12  
13 Lyman M, Lloyd DG, Ji X, Vizcaychipi MP, Ma D. Neuroinflammation: the role and consequences.  
14 *Neurosci Res.* 2014; 79:1–12.

15  
16 Mardiguian S1, Serres S, Ladds E, Campbell SJ, Wilainam P, McFadyen C, McAteer M,  
17 Choudhury RP, Smith P, Saunders F, Watt G, Sibson NR, Anthony DC. Anti-IL-17A treatment  
18 reduces clinical score and VCAM-1 expression detected by in vivo magnetic resonance imaging  
19 in chronic relapsing EAE ABH mice. *Am J Pathol.* 2013; 182:2071-81.

20  
21 Martin KR, Corlett A, Dubach D, Mustafa T, Coleman HA, Parkington HC, et al. Over-expression  
22 of RCAN1 causes Down syndrome-like hippocampal deficits that alter learning and memory. *Hum*  
23 *Mol Genet.* 2012; 21:3025–41.

24  
25 Martínez-Cué C, Martínez P, Rueda N, Vidal R, García S, Vidal V, Corrales A, Montero JA,  
26 Pazos A, Flórez J, Gasser R, Thomas AW, Honer M, Knoflach F, Trejo JL, Wettstein JG,  
27 Hernandez MC. Reducing GABAA  $\alpha$ 5 receptor-mediated inhibition rescues functional and  
28 neuromorphological deficits in a mouse model of Down syndrome. *J Neurosci.* 2013; 33: 3953-  
29 3966.

30  
31 McManus RM, Higgins SC, Mills KH, Lynch MA. Respiratory infection promotes T cell infiltration  
32 and amyloid- $\beta$  deposition in APP/PS1 mice. *Neurobiol Aging.* 2014 35:109-21.

33  
34 Meager A. Cytokines: interleukins. In *Encyclopedia of Molecular Cell Biology and Molecular*  
35 *Medecine*, R. Meyers, Ed. 2004. pp. 115–151. Wilhey-VCH, Weinheim, Germany.

36  
37 Meager A. Viral inhibitors and immune response mediators: the interferons. In *Encyclopedia of*  
38 *Molecular Cell Biology and Molecular Medecine*. R. Meyers, Ed. 2005. pp. 387–421, Wilhey-  
39 VCH, Weinheim, Germany.

40  
41 Meares GP, Ma X, Qin H, Benveniste EN. Regulation of CCL20 expression in astrocytes by IL-6  
42 and IL-17. *Glia.* 2012; 60:771-81.

43  
44 Millan Sanchez M1, Heyn SN, Das D, Moghadam S, Martin KJ, Salehi A. Neurobiological  
45 elements of cognitive dysfunction in down syndrome: exploring the role of APP. *Biol Psychiatry.*  
46 2012; 71: 403-9.

47  
48 Murugaiyan G, Pires da Cunha A, Akay AK, Joller N, Garo LP, Kumaradevan S, Yosef N, Vaidya  
49 VS, Weiner HS. MicroRNA-21 promotes Th17 differentiation and mediates experimental  
50 autoimmune encephalomyelitis. *J. Clin. Invest.* 2015; 126: 1069-80.

51  
52 Mulet M, Blasco-Ibáñez JM, Crespo C, Nácher J, Varea E. Early increased density of  
53 cyclooxygenase-2 (COX-2) immunoreactive neurons in Down syndrome. *Folia Neuropathol.*  
54 2017;55:154-160.

55  
56 Netzer WJ, Powell C, Nong Y, Blundell J, Wong L, Duff K, et al. Lowering beta-amyloid levels  
57 rescues learning and memory in a Down syndrome mouse model. *PLoS One.* 2010; 5: e10943.

1 O'Callaghan JP, Sriram K, Miller DB. Defining "neuroinflammation". *Ann NY Acad Sci.* 2008;  
2 1139:318–30.

3 Onishi RM, Gaffen SL. 2010. Interleukin-17 and its target genes: mechanisms of interleukin-17  
4 function in disease. *Immunology.* 129:311-21.

5 Parisotto EB, Vidal V, García-Cerro S, Lantigua S, Wilhelm Filho D, Sanchez-Barceló EJ,  
6 Martínez-Cué C, Rueda N. Chronic Melatonin Administration Reduced Oxidative Damage and  
7 Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome. *Neurochem*  
8 *Res.* 2016;41:2904-2913.

9  
10  
11 Park JI, Strock CJ, Ball DW, Nelkin BD. Interleukin-1beta can mediate growth arrest and  
12 differentiation via the leukemia inhibitory factor/JAK/ STAT pathway in medullary thyroid  
13 carcinoma cells. *Cytokine.* 2005; 29:125–134.

14  
15 Roberson R, Kuddo T, Horowitz K, Caballero M, Spong CY. Cytokine and chemokine alterations  
16 in Down syndrome. *Am J Perinatol.* 2012; 29:705-708.

17  
18 Rodríguez-Sureda V, Vilches Á, Sánchez O, et al. Intracellular oxidant activity, antioxidant  
19 enzyme defense system, and cell senescence in fibroblasts with trisomy 21. *Oxid Med Cell*  
20 *Longev* 2015; 2015:509241.

21  
22 Rosi S, Belarbi K, Ferguson RA, Fishman K, Obenaus A, Raber J et al. Traum ainduced  
23 alterations in cognition and Arc expression are reduced by previous exposure to 56Fe irradiation.  
24 *Hippocampus.* 2012; 22: 544–554.

25  
26 Rueda N, Martínez-Cué C. Mouse models of Down syndrome and Alzheimer´s disease:  
27 Similarities and differences. In A Salehi, M Rafii, C Phillips (Eds). *Recent Advances in Alzheimer*  
28 *Research.* 2015; 1: 191-250. Bentham Books.

29  
30 Rueda N, Flórez J, Martínez-Cué C. Mouse models of Down syndrome as a tool to unravel the  
31 causes of mental disabilities. *Neural Plast.* 2012; 2012: 584071.

32  
33 Rueda N, Llorens-Martín M, Flórez J, Valdizán E, Banerjee P, Trejo JL, et al. Memantine  
34 normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. *J*  
35 *Alzheimers Dis.* 2010; 21: 277-90.

36  
37 Saab BJ, Saab AMP, Roder JC. Statistical and theoretical considerations for the platform re-  
38 location water maze. *J Neurosci Methods.* 2011; 198: 44-52.

39  
40 Sabbagh MN, Fleisher A, Chen K, Rogers J, Berk C, Reiman E, et al. Positron emission  
41 tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome  
42 and Alzheimer disease. *Arch Neurol.* 2011; 68:1461-6.

43  
44 Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, et al.  
45 Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma  
46 agonists modulate immunostimulated processing of amyloid precursor protein through regulation  
47 of beta-secretase. *J Neurosci.* 2003; 23:9796-804.

48  
49 Seo H, Isacson O. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model  
50 mice. *Exp Neurol.* 2005; 193:469-80.

51  
52 Shastri A, Bonifati DM, Kishore U. Innate immunity and neuroinflammation. *Mediators Inflamm.*  
53 2013;1–19.

54  
55 Sheng JG, Mrak RE, Griffin WS: Neuritic plaque evolution in Alzheimer's disease is accompanied  
56 by transition of activated microglia from primed to enlarged to phagocytic forms. *Acta Neuropathol*  
57 (Berl). 1997; 94:1–5.

1 Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, Griffin WS. In vivo and in  
2 vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in  
3 Alzheimer pathogenesis. *Neurobiol Aging*. 1996; 17:761–766.

4 Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, et al. Pivotal role of cerebral  
5 interleukin-17-producing [gamma][delta]T cells in the delayed phase of ischemic brain injury. *Nat*  
6 *Med*. 2009; 15:946–950.

7  
8 Steele RJ, Morris RG. Delay-dependent impairment of a matching-to-place task with chronic  
9 intrahippocampal infusion of the NMDA-antagonist D-AP5. *Hippocampus*. 1999; 9: 118-136.

10  
11 Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the  
12 induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. *J Exp Med*.  
13 2006; 203:1685-91.

14  
15 Seo H, Isacson O. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model  
16 mice. *Exp Neurol*. 2005; 193: 469-80.

17  
18 Shichiri M, Yoshida Y, Ishida N, Hagihara Y, Iwahashi H, Tamai H, et al.  $\alpha$ -Tocopherol  
19 suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse  
20 model of Down syndrome. *Free Radic Biol Med*. 2011; 50: 1801-11.

21  
22 Shin M, Besser LM, Kucik JE, Lu C, Siffel C, Correa A, et al. Prevalence of Down syndrome  
23 among children and adolescents in 10 regions of the United States. *Pediatrics*. 2009;124(6):1565-  
24 71.

25  
26 Sipos E, Kurunczi A, Kasza A, Horváth J, Felszeghy K, Laroche S, et al. Beta-amyloid pathology  
27 in the entorhinal cortex of rats induces memory deficits: implications for Alzheimer's disease.  
28 *Neuroscience*. 2007;147(1):28-36.

29  
30 St-Amour I, Paré I, Alata W, Coulombe K, Ringuette-Goulet C, Drouin-Ouellet J, Vandal M, Soulet  
31 D, Bazin R, Calon F. Brain bioavailability of human intravenous immunoglobulin and its transport  
32 through the murine blood-brain barrier. *J Cereb Blood Flow Metab*. 2013; 33: 1983-92.

33  
34 Steele M, Stuchbury G, Münch G. The molecular basis of the prevention of Alzheimer's disease  
35 through healthy nutrition. *Exp Gerontol*. 2007; 42:28-36.

36  
37 Sturgeon X, Gardiner KJ. Transcript catalogs of human chromosome 21 and orthologous  
38 chimpanzee and mouse regions. *Mamm Genome*. 2011; 22: 261-71.

39  
40 Swardfager W, Winer DA, Herrmann N, Winer S, Lanctôt KL. Interleukin-17 in post-stroke  
41 neurodegeneration. *Neurosci Biobehav Rev*. 2013 ; 37: 436-47.

42  
43 Teipel SJ, Hampel H. Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's  
44 disease. *Behav Genet*. 2006; 36:405-15.

45  
46 Town T, Nikolic V, Tan J. The microglial "activation" continuum: from innate to adaptive  
47 responses. *Journal of Neuroinflammation*. 2005; 2: 24.

48  
49 Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, et al. Interleukin-17 Production in  
50 Central Nervous System-Infiltrating T Cells and Glial Cells Is Associated with Active Disease in  
51 Multiple Sclerosis. *Am J Pathol*. 2008; 172:146–155.

52  
53 Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents  
54 experimental auto-immune encephalomyelitis. *Eur. J. Immunol*. 2006; 36: 2868–2874.

55  
56 Vidal MA, Walker NJ, Napoli E, et al. Evaluation of senescence in mesenchymal stem cells  
57 isolated from equine bone marrow, adipose tissue, and umbilical cord tissue. *Stem Cells Dev*.  
58 2012; 21: 273–283.

59  
60  
61  
62  
63  
64  
65

1 Villeda SA, Luo J, Mosher KI et al. The ageing systemic milieu negatively regulates neurogenesis  
2 and cognitive function. *Nature*, 2011; 477: 90–94.

3 Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O'Hare E, et al. Fibrillar beta-amyloid  
4 induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a  
5 select population of neurons in the rat CNS in vivo. *J Neurosci*. 1998; 18:2161-73.

6  
7 Wenk GL, McGann K, Mencarelli A, Hauss-Wegrzyniak B, Del Soldato P, Fiorucci S.  
8 Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic  
9 neurons. *Eur J Pharmacol*. 2000; 402:77-85.

10  
11 Wilcock DM. Neuroinflammation in the aging down syndrome brain; Lessons from Alzheimer's  
12 disease. *Curr Gerontol Geriatr Res*. 2012; 1–10.

13  
14 Wilcock DM, Griffin WS. Down's syndrome, neuroinflammation, and Alzheimer  
15 neuropathogenesis. *J Neuroinflammation*. 2013;10:84.

16  
17 Wisniewski KE, Dalton AJ, McLachlan C, Wen GY, Wisniewski HM. Alzheimer's disease in  
18 Down's syndrome: clinicopathologic studies. *Neurology*. 1985; 35:957–961.

19  
20 Wu HP, Shih CC, Chu CM, Huang CY, Hua CC, Liu YC, Chuang DY. Effect of interleukin-17 on in  
21 vitro cytokine production in healthy controls and patients with severe sepsis. *J Formos Med*  
22 *Assoc*. 2015; S0929-6646(14)00321-0.

23  
24 Yang J, Kou J, Lalonde R, Fukuchi KI. Intracranial IL-17A overexpression decreases cerebral  
25 amyloid angiopathy by upregulation of ABCA1 in an animal model of Alzheimer's disease. *Brain*  
26 *Behav Immun*. 2017; 65:262-273.

27  
28 Zimmermann J, Krauthausen M, Hofer MJ, Heneka MT, Campbell IL, Müller M. CNS-Targeted  
29 Production of IL-17A Induces Glial Activation, Microvascular Pathology and Enhances the  
30 Neuroinflammatory Response to Systemic Endotoxemia. *PloSOne*. 2013; e57307.

31  
32 Zhang J, Ke KF, Liu Z, Qiu YH, Peng YP. Th17 cell-mediated neuroinflammation is involved in  
33 neurodegeneration of aβ1-42-induced Alzheimer's disease model rats. *PLoS One*. 2013;  
34 4;8(10):e75786.

35  
36 Zhou L, Chen X, Liu T, et al. Melatonin reverses H<sub>2</sub>O<sub>2</sub>-induced premature senescence in  
37 mesenchymal stem cells via the SIRT1-dependent pathway. *J Pineal Res*. 2015; 59:190-205.

38  
39 Zuercher AW, Spirig R, Baz Morelli A, Käsermann F. IVIG in autoimmune disease - Potential next  
40 generation biologics. *Autoimmun Rev*. 2016; 8:781-785.

Figure 1  
[Click here to download high resolution image](#)




Figure 2






Figure 3




B






## Figure 4

A




B





## Figure 5

A



B





Figure 6

A



B




Figure 7

APP (120 KDa)  
GAPDH (37 KDa)







Figure 8



### Figure 9







Figure 10

